WO2004074246A3 - Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity - Google Patents

Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity Download PDF

Info

Publication number
WO2004074246A3
WO2004074246A3 PCT/US2004/004449 US2004004449W WO2004074246A3 WO 2004074246 A3 WO2004074246 A3 WO 2004074246A3 US 2004004449 W US2004004449 W US 2004004449W WO 2004074246 A3 WO2004074246 A3 WO 2004074246A3
Authority
WO
WIPO (PCT)
Prior art keywords
biphenyl derivatives
antagonist activity
receptor antagonist
receptor agonist
adrenergic receptor
Prior art date
Application number
PCT/US2004/004449
Other languages
French (fr)
Other versions
WO2004074246A2 (en
Inventor
Mathai Mammen
Sarah Dunham
Adam Hughes
Tae Weon Lee
Craig Husfeld
Eric Stangeland
Original Assignee
Theravance Inc
Mathai Mammen
Sarah Dunham
Adam Hughes
Tae Weon Lee
Craig Husfeld
Eric Stangeland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32912274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004074246(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SI200431566T priority Critical patent/SI1615889T1/en
Priority to MXPA05008528A priority patent/MXPA05008528A/en
Priority to NZ541579A priority patent/NZ541579A/en
Priority to KR1020117010078A priority patent/KR101224497B1/en
Priority to EP04711253A priority patent/EP1615889B1/en
Priority to BRPI0407508A priority patent/BRPI0407508B8/en
Priority to AT04711253T priority patent/ATE482934T1/en
Priority to CA2515777A priority patent/CA2515777C/en
Priority to DE602004029347T priority patent/DE602004029347D1/en
Application filed by Theravance Inc, Mathai Mammen, Sarah Dunham, Adam Hughes, Tae Weon Lee, Craig Husfeld, Eric Stangeland filed Critical Theravance Inc
Priority to AU2004213411A priority patent/AU2004213411B2/en
Priority to DK04711253.7T priority patent/DK1615889T3/en
Priority to KR1020057014929A priority patent/KR101223991B1/en
Priority to JP2006503604A priority patent/JP4555283B2/en
Publication of WO2004074246A2 publication Critical patent/WO2004074246A2/en
Publication of WO2004074246A3 publication Critical patent/WO2004074246A3/en
Priority to IL169922A priority patent/IL169922A/en
Priority to IS7964A priority patent/IS2847B/en
Priority to NO20054206A priority patent/NO331947B1/en
Priority to HK06106230.1A priority patent/HK1086266A1/en
Priority to AU2010219338A priority patent/AU2010219338B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9433—(Nor)adrenaline

Abstract

This invention provides biphenyl derivatives of formula I: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
PCT/US2004/004449 2003-02-14 2004-02-13 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity WO2004074246A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
JP2006503604A JP4555283B2 (en) 2003-02-14 2004-02-13 Biphenyl derivatives having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity
DK04711253.7T DK1615889T3 (en) 2003-02-14 2004-02-13 Biphenyl derivatives with beta2-adrenergic receptor agonist and muscarinic receptor antagonist activity
AU2004213411A AU2004213411B2 (en) 2003-02-14 2004-02-13 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
KR1020057014929A KR101223991B1 (en) 2003-02-14 2004-02-13 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
MXPA05008528A MXPA05008528A (en) 2003-02-14 2004-02-13 Biphenyl derivatives.
BRPI0407508A BRPI0407508B8 (en) 2003-02-14 2004-02-13 biphenyl derivative compounds, pharmaceutical composition and use thereof
AT04711253T ATE482934T1 (en) 2003-02-14 2004-02-13 BIPHENYL DERIVATIVES WITH BETA2 ADRENERG RECEPTOR AGONISTIC AND MUSCARIN RECEPTOR ANTAGONISTIC ACTIVITY
CA2515777A CA2515777C (en) 2003-02-14 2004-02-13 Biphenyl derivatives
DE602004029347T DE602004029347D1 (en) 2003-02-14 2004-02-13 BIPHENYL DERIVATIVES WITH BETA2 ADRENERG RECEPTOR AGONISTIC AND MUSCARIN RECEPTOR OF ANTAGONISTIC ACTIVITY
SI200431566T SI1615889T1 (en) 2003-02-14 2004-02-13 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
NZ541579A NZ541579A (en) 2003-02-14 2004-02-13 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP04711253A EP1615889B1 (en) 2003-02-14 2004-02-13 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
KR1020117010078A KR101224497B1 (en) 2003-02-14 2004-02-13 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
IL169922A IL169922A (en) 2003-02-14 2005-07-27 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
IS7964A IS2847B (en) 2003-02-14 2005-07-28 Biphenyl derivatives with beta2 adrenergic receptor antagonist and muscarinic receptor antagonist activity
NO20054206A NO331947B1 (en) 2003-02-14 2005-09-09 Biphenyl derivative, its use and pharmaceutical composition comprising the compound.
HK06106230.1A HK1086266A1 (en) 2003-02-14 2006-05-29 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
AU2010219338A AU2010219338B2 (en) 2003-02-14 2010-09-08 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44784303P 2003-02-14 2003-02-14
US60/447,843 2003-02-14
US46703503P 2003-05-01 2003-05-01
US60/467,035 2003-05-01

Publications (2)

Publication Number Publication Date
WO2004074246A2 WO2004074246A2 (en) 2004-09-02
WO2004074246A3 true WO2004074246A3 (en) 2004-11-18

Family

ID=32912274

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2004/004449 WO2004074246A2 (en) 2003-02-14 2004-02-13 Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
PCT/US2004/004224 WO2004074276A1 (en) 2003-02-14 2004-02-13 BIPHENYL DERIVATIVES HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
PCT/US2004/004273 WO2004074812A2 (en) 2003-02-14 2004-02-13 Library of biphenyl derivatives useful for identifying compounds having both beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2004/004224 WO2004074276A1 (en) 2003-02-14 2004-02-13 BIPHENYL DERIVATIVES HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
PCT/US2004/004273 WO2004074812A2 (en) 2003-02-14 2004-02-13 Library of biphenyl derivatives useful for identifying compounds having both beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Country Status (28)

Country Link
US (15) US20040209915A1 (en)
EP (5) EP1615889B1 (en)
JP (6) JP4555283B2 (en)
KR (3) KR101223991B1 (en)
AR (1) AR043176A1 (en)
AT (1) ATE482934T1 (en)
AU (2) AU2004213411B2 (en)
BR (1) BRPI0407508B8 (en)
CA (1) CA2515777C (en)
CY (2) CY1111276T1 (en)
DE (1) DE602004029347D1 (en)
DK (2) DK1615889T3 (en)
ES (2) ES2566155T3 (en)
HK (3) HK1086266A1 (en)
HU (1) HUE027380T2 (en)
IL (1) IL169922A (en)
IS (1) IS2847B (en)
MX (1) MXPA05008528A (en)
MY (1) MY148487A (en)
NO (2) NO331947B1 (en)
NZ (1) NZ541579A (en)
PE (1) PE20040950A1 (en)
PL (1) PL216397B1 (en)
PT (1) PT1615889E (en)
RU (1) RU2330841C2 (en)
SI (2) SI2246345T1 (en)
TW (1) TWI331995B (en)
WO (3) WO2004074246A2 (en)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
PE20050130A1 (en) * 2002-08-09 2005-03-29 Novartis Ag ORGANIC COMPOUNDS
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
PE20040950A1 (en) 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
WO2004106333A1 (en) * 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
PT1631295E (en) * 2003-06-06 2010-05-24 Arexis Ab Use of condensed heterocyclic compounds as scce inhibitors for the treatment of skin diseases
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
ES2329586T3 (en) * 2003-11-21 2009-11-27 Theravance, Inc. COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE BETA2 ADRENERGIC RECEIVER AND ANTAGONIST OF THE MUSCARINE RECEIVER.
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
WO2005080375A1 (en) * 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
EP1723115A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528412A (en) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087735A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528408A (en) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド Useful biphenyl compounds as muscarinic receptor antagonists
EP1723113A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7501442B2 (en) * 2004-03-11 2009-03-10 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
ES2317245T3 (en) * 2004-05-31 2009-04-16 Laboratorios Almirall, S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
JP2008510014A (en) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド Compounds having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
GT200500281A (en) 2004-10-22 2006-04-24 Novartis Ag ORGANIC COMPOUNDS.
US20090258858A1 (en) * 2004-10-29 2009-10-15 Jakob Busch-Petersen Muscarinic acetylcholine receptor antagonists
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7642355B2 (en) 2005-03-10 2010-01-05 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099031A1 (en) * 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2008533028A (en) * 2005-03-10 2008-08-21 セラヴァンス， インコーポレーテッド Biphenyl compounds useful as muscarinic receptor antagonists
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
ES2265276B1 (en) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
JP2008546695A (en) 2005-06-13 2008-12-25 セラヴァンス， インコーポレーテッド Biphenyl compounds useful as muscarinic receptor antagonists
US8429052B2 (en) * 2005-07-19 2013-04-23 Lincoln National Life Insurance Company Method and system for providing employer-sponsored retirement plan
BRPI0614290A2 (en) 2005-08-08 2011-03-22 Argenta Discovery Ltd bicyclo [2.2.1] hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
AR058104A1 (en) 2005-10-21 2008-01-23 Novartis Ag ORGANIC COMPOUNDS
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
US7973055B2 (en) * 2006-03-09 2011-07-05 Theravance, Inc. Crystalline forms of a biphenyl compound
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
JP2009530364A (en) 2006-03-20 2009-08-27 ファイザー・リミテッド Amine derivatives
JP5373599B2 (en) 2006-04-21 2013-12-18 ノバルティス アーゲー Purine derivatives for use as adenosine A2A receptor agonists
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
ES2296516B1 (en) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0711558A2 (en) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polymorphs
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
GB0613154D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
WO2008041095A1 (en) * 2006-10-04 2008-04-10 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
ES2302447B1 (en) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
ATE493174T1 (en) 2007-01-10 2011-01-15 Irm Llc COMPOUNDS AND COMPOSITIONS AS CHANNEL-ACTIVATE PROTEASE INHIBITORS
PT2119700E (en) * 2007-01-31 2012-10-02 Toray Industries Benzylamine derivative or pharmaceutically acceptable acid addition salt thereof, and use thereof for medical purposes
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
ES2306595B1 (en) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 .
US8682466B2 (en) * 2007-05-04 2014-03-25 Taiwan Semiconductor Manufacturing Company, Ltd. Automatic virtual metrology for semiconductor wafer result prediction
KR20100005730A (en) 2007-05-07 2010-01-15 노파르티스 아게 Organic compounds
ES2320961B1 (en) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) PHENOL AS BETA2 ADRENERGIC RECEIVER AGONISTS.
ES2602331T3 (en) 2007-12-10 2017-02-20 Novartis Ag Pyrazin-carboxamides of the amiloride type as ENaC blockers
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
DK2242759T3 (en) * 2008-02-06 2012-12-17 Astrazeneca Ab compounds
EP2096105A1 (en) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
MX2010013675A (en) 2008-06-10 2011-02-15 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers.
AU2009260899B2 (en) 2008-06-18 2012-02-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010007561A1 (en) * 2008-07-15 2010-01-21 Pfizer Limited Novel compounds active as muscarinic receptor antagonists
US20100016366A1 (en) * 2008-07-15 2010-01-21 Paul Alan Glossop Novel Compounds Active as Muscarinic Receptor Antagonists
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
UY32297A (en) 2008-12-22 2010-05-31 Almirall Sa MESILATE SALT OF 5- (2 - {[6- (2,2-DIFLUORO-2-PHENYLITOXI) HEXIL] AMINO} -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONA AS A RECEIVER AGONIST B (BETA ) 2 ACRENERGIC
JP2012512848A (en) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Salt forms of organic compounds
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2409977A4 (en) 2009-03-17 2012-09-26 Daiichi Sankyo Co Ltd Amide derivative
SG175023A1 (en) * 2009-04-14 2011-11-28 Glaxo Group Ltd Process for the preparation of a biphenyl-2-ylcarbamic acid ester
ES2715965T3 (en) 2009-04-23 2019-06-07 Theravance Respiratory Co Llc Diamine compounds that have muscarinic receptor antagonist activity and beta 2 adrenergic receptor agonist
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2426121A4 (en) * 2009-04-30 2012-10-31 Teijin Pharma Ltd Quaternary ammonium salt compound
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
KR20210033559A (en) 2009-11-27 2021-03-26 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (en) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES
KR101742253B1 (en) * 2010-07-13 2017-05-31 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Process for preparing a biphenyl-2-ylcarbamic acid
CN103097385B (en) 2010-07-14 2016-08-03 诺华股份有限公司 IP receptor stimulating agent heterocyclic compound
WO2012032546A2 (en) * 2010-09-08 2012-03-15 Cadila Healthcare Limited Process for the preparation of salmeterol and its intermediates
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (en) 2010-09-09 2012-04-30 Irm Llc COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR083115A1 (en) * 2010-09-30 2013-01-30 Theravance Inc CRYSTAL OXALATE SALTS OF A DIAMID COMPOUND
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
JP6060242B2 (en) * 2010-11-30 2017-01-11 株式会社日立国際電気 Substrate processing apparatus, semiconductor device manufacturing method, and baffle structure
CN103492384B (en) 2011-02-25 2016-05-11 诺华股份有限公司 As compound and the composition of TRK inhibitor
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
SI2718280T1 (en) 2011-06-10 2015-12-31 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
BR112013030302B1 (en) * 2011-06-10 2021-08-24 Chiesi Farmaceutici S.P.A. COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, COMPOSITION OF A COMPOUND AND DEVICE
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
JP5886433B2 (en) 2011-09-16 2016-03-16 ノバルティス アーゲー Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2802584B1 (en) 2012-01-13 2015-11-18 Novartis AG Salts of an ip receptor agonist
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
TW201335160A (en) 2012-01-13 2013-09-01 Novartis Ag IP receptor agonist heterocyclic compounds
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105065A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014044288A1 (en) * 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
PL2928890T3 (en) 2012-12-06 2018-07-31 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PE20151216A1 (en) 2012-12-06 2015-09-08 Chiesi Farma Spa COMPOUNDS WITH ANTAGONISTIC ACTIVITY OF THE MUSCARINAL RECEPTORS AND AGONISTIC ACTIVITY OF THE BETA2 ADRENERGIC RECEPTOR
KR20150096732A (en) * 2012-12-18 2015-08-25 알미랄, 에스.에이. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
CN105189500A (en) 2013-02-13 2015-12-23 诺华股份有限公司 IP receptor agonist heterocyclic compounds
TWI643853B (en) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CZ306252B6 (en) 2013-03-15 2016-10-26 Zentiva, K.S. Process for preparing 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-quinolin-2-one (indacaterol)
EP3022201A1 (en) 2013-07-18 2016-05-25 Novartis AG Autotaxin inhibitors
AU2014291711B2 (en) 2013-07-18 2017-02-02 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
TWI641373B (en) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES
TW201517906A (en) 2013-07-25 2015-05-16 Almirall Sa Combinations comprising MABA compounds and corticosteroids
ES2950384T3 (en) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Medical use of a DPP-4 inhibitor
MX2016013812A (en) 2014-04-24 2017-03-09 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors.
KR20160145780A (en) 2014-04-24 2016-12-20 노파르티스 아게 Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
ES2667424T3 (en) 2014-04-24 2018-05-10 Novartis Ag Pyrazine derivatives as phosphatidyl-inositol-3-kinase inhibitors
TW201617343A (en) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities
TWI703138B (en) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
AR104828A1 (en) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPOUNDS WITH ANTAGONIST ACTIVITY OF THE MUSCARINIC RECEIVERS AND AGONIST ACTIVITY OF THE ADRENERGIC RECEIVER b2
WO2017001907A1 (en) * 2015-06-29 2017-01-05 Teva Pharmaceuticals International Gmbh Biocatalytic processes for the preparation of vilanterol
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX2018008799A (en) * 2016-01-22 2019-01-14 Sichuan Haisco Pharmaceutical Co Ltd Nitrogenous heterocyclic amide derivative, preparation method thereof, and pharmaceutical application.
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
EP3484879B1 (en) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN106706868B (en) * 2016-11-15 2018-12-04 河南省农业科学院 Application of the artificial expression HSP27 albumen in terms of detecting beta-2-adrenoreceptor agonists class medicament residue
EP3556435B1 (en) 2016-12-14 2020-10-28 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quaternary ammonium salt structure
CN106632257B (en) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 The synthetic method of GSK961081 and its intermediate
US11866482B2 (en) 2018-02-07 2024-01-09 Duke University System and method for homogenous GPCR phosphorylation and identification of beta-2 adrenergic receptor positive allosteric modulators
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
CA3139634A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CA3146109A1 (en) 2019-08-28 2021-03-04 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
WO2022175982A1 (en) * 2021-02-19 2022-08-25 Gbr Laboratories Private Limited A process for preparing batefenterol and intermediates thereof
CN114409890A (en) * 2022-02-28 2022-04-29 中国科学院长春应用化学研究所 Amino-functionalized polyethylene glycol derivative and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064031A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. β2-ADRENERGIC RECEPTOR AGONISTS
WO2001042213A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Urea compounds having muscarinic receptor antagonist activity
WO2001042212A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026897A (en) * 1974-01-31 1977-05-31 Otsuka Pharmaceutical Company 5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
BR8007911A (en) 1979-12-06 1981-06-16 Glaxo Group Ltd PERFECTED INHALER
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
DE3134590A1 (en) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim NEW BENZO HETEROCYCLES
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
PT83094B (en) 1985-07-30 1993-07-30 Glaxo Group Ltd DEVICES PROPER FOR THE ADMINISTRATION OF MEDICINES TO PATIENTS
US4894219A (en) 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
DK443489D0 (en) 1989-09-08 1989-09-08 Ferrosan As SUBSTITUTED URINARY COMPOUNDS, THEIR PREPARATION AND USE
SK280967B6 (en) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalation device
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
ES2216800T3 (en) 1991-12-18 2004-11-01 Minnesota Mining And Manufacturing Company AEROSOL FORMULATIONS IN SUSPENSION.
HUT72321A (en) 1992-03-31 1996-04-29 Glaxo Group Ltd Substituted phenylcarbamate and phenyl-urea derivatives, pharmaceutical compositions containing them and process for their preparation
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (en) 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
WO1995021820A1 (en) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
US5495054A (en) 1994-05-31 1996-02-27 Sepracor, Inc. Tetrahydroindeno[1,2-D][1,3,2]oxazaboroles and their use as enantioselective catalysts
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
SE9501384D0 (en) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
SK284447B6 (en) 1995-04-14 2005-04-01 Glaxo Wellcome Inc. Metered dose inhaler
DE19536902A1 (en) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Miniature fluid pressure generating device
EP0863141B1 (en) 1995-10-13 2001-09-12 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
PE92198A1 (en) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd DERIVATIVES OF FLUORINE-CONTAINED 1,4-PIPERIDINE
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
JP2002508366A (en) 1997-12-12 2002-03-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Quinoline piperazine and quinoline piperidine derivatives, methods for their preparation, and their use as complex 5-HT1A, 5-HT1B and 5-HT1D receptor antagonists
SI1070056T1 (en) 1998-03-14 2004-12-31 Altana Pharma Ag Phthalazinone pde iii/iv inhibitors
PT1073417E (en) 1998-04-18 2003-04-30 Glaxo Group Ltd PHARMACEUTICAL FORMULA IN AEROSOL
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
AU763638B2 (en) 1998-06-08 2003-07-31 Theravance Biopharma R&D Ip, Llc Muscarinic receptor antagonists
SE9804000D0 (en) 1998-11-23 1998-11-23 Astra Ab New composition of matter
WO2000035877A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (en) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
DK1169019T3 (en) 1999-04-14 2003-06-02 Glaxo Group Ltd Pharmaceutical aerosol formulation
US6593497B1 (en) * 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6933296B2 (en) 2000-06-05 2005-08-23 Altana Pharma B.V. Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors
IL156499A0 (en) 2000-12-22 2004-01-04 Almirall Prodesfarma Ag Quinuclidine carbamate derivatives and their use as m3 antagonists
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60220887T2 (en) 2001-03-08 2008-02-28 Glaxo Group Ltd., Greenford AGONISTS OF BETA ADRENORE RECEPTORS
JP4143413B2 (en) 2001-03-22 2008-09-03 グラクソ グループ リミテッド Formanilide derivatives as β2-adrenergic receptor agonists
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US7361787B2 (en) 2001-09-14 2008-04-22 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
BR0309185A (en) 2002-04-12 2005-02-15 Boehringer Ingelheim Pharma Beta-mimetic drug and a new anticholinergic
WO2003099764A1 (en) * 2002-05-28 2003-12-04 Theravance, Inc. ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS
US6711451B2 (en) * 2002-07-02 2004-03-23 3D Systems, Inc. Power management in selective deposition modeling
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
PE20040950A1 (en) * 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
US7317102B2 (en) * 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
WO2004106333A1 (en) * 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
JP2007524641A (en) * 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド Substituted 4-amino-1-benzylpiperidine compounds
ES2329586T3 (en) 2003-11-21 2009-11-27 Theravance, Inc. COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE BETA2 ADRENERGIC RECEIVER AND ANTAGONIST OF THE MUSCARINE RECEIVER.
WO2005080375A1 (en) * 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
US7501442B2 (en) * 2004-03-11 2009-03-10 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528408A (en) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド Useful biphenyl compounds as muscarinic receptor antagonists
WO2005087735A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528412A (en) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド Biphenyl compounds useful as muscarinic receptor antagonists
EP1723113A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7071224B2 (en) * 2004-03-11 2006-07-04 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
JP2008510014A (en) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド Compounds having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064031A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. β2-ADRENERGIC RECEPTOR AGONISTS
WO1999064035A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. β2-ADRENERGIC RECEPTOR AGONISTS
WO2001042213A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Urea compounds having muscarinic receptor antagonist activity
WO2001042212A1 (en) * 1999-12-07 2001-06-14 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
CA2515777A1 (en) 2004-09-02
RU2330841C2 (en) 2008-08-10
JP2006517978A (en) 2006-08-03
AU2010219338A1 (en) 2010-09-30
KR20110132634A (en) 2011-12-08
US20060229334A1 (en) 2006-10-12
ES2636480T3 (en) 2017-10-05
NO333394B1 (en) 2013-05-27
DE602004029347D1 (en) 2010-11-11
JP2010159291A (en) 2010-07-22
US8618131B2 (en) 2013-12-31
CA2515777C (en) 2013-01-22
DK2246345T3 (en) 2016-05-02
US20070088054A1 (en) 2007-04-19
NO20054206L (en) 2005-10-19
IS7964A (en) 2005-07-28
US20040209915A1 (en) 2004-10-21
MXPA05008528A (en) 2005-10-20
US7507751B2 (en) 2009-03-24
HUE027380T2 (en) 2016-09-28
AU2004213411B2 (en) 2010-06-24
JP5247757B2 (en) 2013-07-24
ES2566155T3 (en) 2016-04-11
IL169922A (en) 2013-08-29
JP2007119496A (en) 2007-05-17
EP1594860A2 (en) 2005-11-16
US20040209860A1 (en) 2004-10-21
TWI331995B (en) 2010-10-21
HK1216892A1 (en) 2016-12-09
US20070037984A1 (en) 2007-02-15
BRPI0407508B8 (en) 2021-05-25
JP2006518739A (en) 2006-08-17
US20140235864A1 (en) 2014-08-21
HK1149548A1 (en) 2011-10-07
KR20050102114A (en) 2005-10-25
WO2004074276A1 (en) 2004-09-02
US7524959B2 (en) 2009-04-28
US8969571B2 (en) 2015-03-03
PE20040950A1 (en) 2005-01-01
US20040167167A1 (en) 2004-08-26
AR043176A1 (en) 2005-07-20
US7345175B2 (en) 2008-03-18
KR101223991B1 (en) 2013-01-21
US7141671B2 (en) 2006-11-28
PL378025A1 (en) 2006-02-20
NO20120150L (en) 2005-10-19
US20070276003A1 (en) 2007-11-29
EP2246345A1 (en) 2010-11-03
JP5436503B2 (en) 2014-03-05
US20080015220A1 (en) 2008-01-17
US20060223859A1 (en) 2006-10-05
EP3012254A1 (en) 2016-04-27
EP1615889A2 (en) 2006-01-18
US8242135B2 (en) 2012-08-14
US20070208176A1 (en) 2007-09-06
RU2005128557A (en) 2006-03-20
ATE482934T1 (en) 2010-10-15
US7521561B2 (en) 2009-04-21
WO2004074812A2 (en) 2004-09-02
AU2010219338B2 (en) 2012-07-12
BRPI0407508A (en) 2006-02-14
CY1117459T1 (en) 2017-04-26
SI2246345T1 (en) 2016-06-30
US20060223858A1 (en) 2006-10-05
US7355046B2 (en) 2008-04-08
EP3012254B1 (en) 2017-05-17
US7829583B2 (en) 2010-11-09
HK1086266A1 (en) 2006-09-15
NO331947B1 (en) 2012-05-07
US20110312994A1 (en) 2011-12-22
PL216397B1 (en) 2014-03-31
US20130150404A1 (en) 2013-06-13
KR101224497B1 (en) 2013-01-23
EP1615889B1 (en) 2010-09-29
CY1111276T1 (en) 2015-08-05
NO20054206D0 (en) 2005-09-09
PT1615889E (en) 2010-12-09
KR20110053393A (en) 2011-05-20
JP4555283B2 (en) 2010-09-29
IS2847B (en) 2013-09-15
WO2004074276B1 (en) 2004-10-07
WO2004074246A2 (en) 2004-09-02
BRPI0407508B1 (en) 2015-12-01
AU2004213411A1 (en) 2004-09-02
JP2006517971A (en) 2006-08-03
US20060223860A1 (en) 2006-10-05
US7514558B2 (en) 2009-04-07
WO2004074812A3 (en) 2004-11-04
US7879879B2 (en) 2011-02-01
MY148487A (en) 2013-04-30
TW200424173A (en) 2004-11-16
JP2011225617A (en) 2011-11-10
EP1592685A1 (en) 2005-11-09
SI1615889T1 (en) 2011-01-31
EP2246345B1 (en) 2016-02-10
DK1615889T3 (en) 2010-12-20
NZ541579A (en) 2008-08-29

Similar Documents

Publication Publication Date Title
WO2004074246A3 (en) Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2004089892A3 (en) Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
DE602004021921D1 (en) AZABICYCLOALKAN COMPOUNDS AS MUSCARIN RECEPTOR ANTAGONISTS
FIC20210022I1 (en) tucatinib, optionally in the form of a pharmaceutically acceptable salt or solvate
WO2007127196A3 (en) DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2005051946A3 (en) Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2002074758A3 (en) Novel amines as histamine-3 receptor ligands and their therapeutic applications
MXPA04003439A (en) 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists.
WO2006038006A3 (en) 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
WO2006007540A3 (en) Piperidine derivatives as nk1 antagonists
WO2006098761A3 (en) Hsp90 inhibitors, methods of making and uses therefor
MX2008001606A (en) Substituted piperazines as metabotropic glutamate receptor antagonists.
WO2009039461A3 (en) N-substituted piperidine derivatives as serotonin receptor agents
WO2009035542A3 (en) Guanidine-containing compounds useful as muscarinic receptor antagonists
WO2006066173A3 (en) Novel mch receptor antagonists
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2007143523A8 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
ATE475640T1 (en) ANTAGONISTS OF THE OPIOID RECEPTOR
TW200604165A (en) Novel benzyl(idene)-lactam derivatives
MXPA04006555A (en) 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists.
MX2009008527A (en) Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists.
WO2008011113A3 (en) Thiadiazolidinone derivatives
WO2007079003A3 (en) Amide inhibitors of leukotriene a4 hydrolase
RS20050892A (en) Imidazole derivatives as glutamate receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 169922

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004213411

Country of ref document: AU

Ref document number: 3375/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 541579

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005/06215

Country of ref document: ZA

Ref document number: 200506215

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 05079299

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2515777

Country of ref document: CA

Ref document number: PA/a/2005/008528

Country of ref document: MX

Ref document number: 378025

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2006503604

Country of ref document: JP

Ref document number: 1020057014929

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2004213411

Country of ref document: AU

Date of ref document: 20040213

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004213411

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004711253

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20048065284

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2005128557

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020057014929

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1-2005-501486

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 2004711253

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0407508

Country of ref document: BR